Skip to main content

Table 4 Antibiotics used for empiric and definitive therapy among the patients

From: Mortality and its predictors among hospitalized patients with infections due to extended spectrum beta-lactamase (ESBL) Enterobacteriaceae in Malaysia: a retrospective observational study

Variable Frequency Percentage (%)
Active empiric therapy 31 28.2
Empiric antibiotics used (n = 129)
Piperacillin–tazobactam 29 23.6
Ceftriaxone 15 12.2
Cefuroxime 13 10.6
Meropenem 12 9.8
Ampicillin-sulbactam 12 9.8
Ciprofloxacin 8 6.5
Amoxicillin-clavulanate 6 4.9
Metronidazole 6 4.9
Ceftazidime 4 3.3
Vancomycin 4 3.3
Cefoperazone 4 3.3
Azithromycin 4 3.3
Imipenem 2 1.6
Trimethoprim/sulfamethoxazole 2 1.6
Clindamycin 1 0.8
Cefepime 1 0.8
Combination empiric therapy 15 13.6
Definitive antibiotics (n = 92)
Meropenem 74 80.4
Imipenem 9 9.8
Ciproflocaxin 4 4.3
Piperacillin–tazobactam 3 3.3
Trimethoprim/sulfamethoxazole 1 1.1
Ertapenem 1 1.1
Combination definitive therapy 6 5.5
Mean duration before active antibiotics 3.9 ± 2.7